EGFR and head and neck squamous cell carcinoma: Similarly, only NCT03370276, the phase II study of nivolumab and cetuximab (NCT03370276) and the control arm of Checkmate 714 reported higher ORRs in the HPV− group.16 These findings align with prior observations that the efficacy of cetuximab and other EGFR-targeted therapies is lower in HPV + HNSCC.5